Hence, SUMOylation inhibitors can reduce FXR signaling, which amplifies the effect of FXR agonists, thereby improving the therapeutic efficacy of FXR agonists for activated HSCs and liver fibrosis. The gene discussed is NR1H4; the disease is Hepatic fibrosis.